

Received Date : 24-Nov-2015

Revised Date : 28-Dec-2015

Accepted Date : 14-Jan-2016

Article type : Review Article

First decision date: 12-Dec-2015

Running head: Sarcopenia in cirrhosis

Review article: Sarcopenia in cirrhosis – aetiology, implications and potential therapeutic interventions

Marie Sinclair<sup>1,3</sup>, Paul J Gow<sup>1,3</sup>, Mathis Grossmann<sup>2,3</sup>, Peter W Angus<sup>1,3</sup>

1. Liver Transplant Unit, Austin Hospital, Melbourne, Australia, 3084
2. Endocrinology Unit, Austin Hospital, Melbourne, Australia, 3084
3. The University of Melbourne, Department of Medicine, Melbourne, Australia, 3050

Corresponding author:

Dr Marie Sinclair: study design, research/literature collation, formulating draft

[marie.sinclair@austin.org.au](mailto:marie.sinclair@austin.org.au), Ph +613 94965353, Fax +613 94963487

Liver Transplant Unit, Austin Hospital

145 Studley Road, Heidelberg

Melbourne, Victoria

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/apt.13549](https://doi.org/10.1111/apt.13549)

This article is protected by copyright. All rights reserved

Australia 3084

Associate Professor Paul J Gow: formulating draft of manuscript, critical revision

[Paul.gow@austin.org.au](mailto:Paul.gow@austin.org.au), Ph +613 94965353

Professor Peter W Angus: formulating draft of manuscript, critical revision

[Peter.angus@austin.org.au](mailto:Peter.angus@austin.org.au), Ph +613 94965353

Associate Professor Mathis Grossmann: formulating draft of manuscript, critical revision

[mathisg@unimelb.edu.au](mailto:mathisg@unimelb.edu.au), Ph +613 94965135

Keywords: liver disease, muscle mass, mortality, myostatin, malnutrition

There are no conflicts of interest to report in the writing of this manuscript. An Australian Postgraduate Award from the University of Melbourne to Marie Sinclair assisted in the production of this work

## **Abstract**

Background:

Sarcopenia is common in cirrhosis and is associated with poor outcomes. Current teaching recommends the use of protein supplementation and exercise, however this fails to address many other factors which contribute to muscle loss in this setting.

Aims:

This review summarises existing knowledge regarding the aetiology of sarcopenia in cirrhosis, diagnostic modalities, and the clinical significance of this condition. It also discusses recent research findings that may allow the development of more effective treatments.

Methods:

This article is protected by copyright. All rights reserved

We conducted a Medline and Pubmed search using the search terms “sarcopenia”, “muscle”, “body composition”, “cirrhosis”, “liver” and “malnutrition” from inception to October 2015.

Results:

Cirrhotic patients with sarcopenia have reduced survival, experience increased rates of infection and have worse outcomes following liver transplantation. The aetiology of this condition is more complex than simple protein and calorie malnutrition. Cirrhosis also results in depleted glycogen stores and metabolic alterations that cause excessive protein catabolism, increased activation of the ubiquitin proteasome pathway and inappropriate muscle autophagy. Satellite cell differentiation and proliferation is also reduced due to a combination of elevated myostatin levels, reduced IGF-1 and hypogonadism. Although there is some evidence supporting the use of late evening snacks, branched chain amino acid supplementation and high protein / high calorie diets, well design clinical trials addressing the effects of treatment on body composition in cirrhosis are lacking.

Conclusion:

Sarcopenia in cirrhosis has a complex pathogenesis and simple dietary interventions are of limited benefit. Improved understanding of the multiple mechanisms involved should allow the development of more effective therapies which target the specific underlying metabolic derangements.

## **Introduction**

Loss of muscle mass and function, or sarcopenia, is one of commonest features of cirrhosis and contributes significantly to morbidity and mortality in this population. Its prevalence in patients with cirrhosis is estimated to be 40-70% and thus it currently affects over 300,000 people in the United States (1-4). To put this into context, the annual incidence of bleeding oesophageal varices in cirrhosis is 10-15%, refractory ascites is 5-10% and hepatocellular carcinoma occurs in 3-5% (5). Only overt hepatic encephalopathy has similar prevalence, and interestingly has a close correlation with the presence of sarcopenia (6) (7). The prevalence of sarcopenia in cirrhosis is far higher than in other gastrointestinal illness due to the unique metabolic derangements caused by liver failure. The prevalence in inflammatory bowel disease for example is only 21% (8).

Despite this, there are no established criteria for the diagnosis of this important complication of cirrhosis, its pathogenesis is poorly understood and none of the proposed treatment options have been well explored in randomised clinical trials. This review aims to summarise current understanding of the pathogenesis of sarcopenia in patients with cirrhosis, discusses possible treatment options and highlights potential avenues for future research.

We conducted a Medline and Pubmed search from inception to October 2015 using the search terms “sarcopenia”, “muscle”, “body composition”, “cirrhosis”, “liver” and “malnutrition”. This was followed by a manual review of the literature to select articles that specifically addressed the diagnosis, aetiology, implication or treatment of sarcopenia in cirrhosis.

### **Normal regulation of muscle mass in adults**

The regulation of muscle mass and function in adults is tightly controlled by various genes and transcription factors that affect protein production, recruitment and differentiation of satellite cells and muscle breakdown. These pathways are summarised in Figure 1.

#### Muscle protein synthesis

Activation of the intracellular target mTOR (mammalian target of rapamycin) stimulates protein synthesis via various intracellular signalling pathways. mTOR is activated via protein kinase B (PCK/AKT), which is upregulated by insulin, insulin-like growth factor (IGF-1), circulating testosterone, physical exercise, and branched chain amino acids (BCAAs), particularly leucine (9).

#### Satellite cell differentiation and proliferation

Muscle growth and repair also requires the recruitment and proliferation of satellite cells, which are the precursors to new muscle fibres. Protein kinase B (PCK/AKT), which is directly activated by IGF-1, stimulates this activation of satellite cells. This pathway is upregulated by BCAAs, exercise and testosterone (10, 11).

Myostatin is the major negative regulator of satellite cell differentiation and proliferation. It belongs to the transforming growth factor- $\beta$  superfamily of secreted growth and differentiation factors. It acts in a paracrine fashion to maintain satellite cells in a quiescent state within muscle. IGF-1 has dual action in that it stimulates mTOR as well as inhibits

myostatin, thereby stimulating muscle growth by both activating satellite cells and muscle protein synthesis (12).

### Proteolysis

The two major skeletal muscle proteolytic pathways are the ubiquitin-proteasome pathway (UPP) and the autophagy system. The UPP is the major muscle break-down pathway, and involves the tagging of protein by conjugation with ubiquitin and then subsequent degradation by the 26S proteasome. Protein kinase B (PCK/AKT) inhibits proteolysis via the UPP and both inactivity and systemic inflammation activate the UPP. Autophagy is a programmed cell death pathway activated in response to cell stress of any aetiology that involves the fusing of a cell to a lysosome which then degrades cellular contents (13).

### **Aetiology of sarcopenia in cirrhosis**

There are multiple factors which may contribute to sarcopenia in cirrhosis, although their precise roles are poorly understood (Figure 2). Ultimately, this condition results from an imbalance between muscle formation and muscle breakdown, although the specific pathways involved may differ between patients. Understanding the role of these potential contributors will help provide a rational basis for developing strategies to prevent and treat muscle loss in patients with advanced cirrhosis and to minimise its impact on patient quality of life, morbidity and mortality.

### Malnutrition - reduced substrate for muscle production

Malnutrition is believed to play a major role in sarcopenia in cirrhosis. A reduced total energy intake has been linked with a higher prevalence of sarcopenia in patients with cirrhosis. For example, one observational study of 50 patients reported a median caloric intake of 1544 kcal in sarcopenia patients compared to 1783 kcal in non-sarcopenic patients ( $p=0.001$ ) (14). However this does not necessarily prove causality since lower caloric intake may more broadly reflect general ill health. There are many potential causes of reduced dietary intake in cirrhotics including nausea and anorexia induced by elevated inflammatory mediators such as TNF-alpha; increased intra-abdominal pressure from ascites; abdominal pain; and altered gut motility (15). Dysgeusia is common in cirrhosis, and salt restriction may also affect enjoyment of food, both of which also may affect caloric intake (16).

Patients may also have inadequate dietary protein intake due to inappropriate and outdated advice that protein restriction is required to prevent encephalopathy.

Even with adequate caloric intake, malabsorption may contribute to net negative energy balance in cirrhosis. It is well recognised that reduced bile flow can cause malabsorption of fats and fat-soluble vitamins including vitamin D (17). There is also increasing evidence that altered gut motility, small bowel bacterial overgrowth and changes to the gut microbiota in cirrhosis can each affect both absorption and utilization of nutrients (18). Alcohol abuse may result in concomitant pancreatic insufficiency, which can also impair nutrient absorption.

#### Elevated myostatin and inhibition of muscle growth

Myostatin is the predominant negative regulator of satellite cell differentiation and proliferation. Elevated myostatin levels are thought to be one of the major driving forces underlying the sarcopenia of ageing, however the reasons for this elevation are not fully understood (19). Blocking myostatin increases muscle strength and function in animal models of sarcopenia of ageing (20) which further strengthens its aetiological role. Patients with cirrhosis have been shown to have significantly higher serum levels of myostatin than controls (0.53mcg/mL vs 0.13 mcg/mL in cirrhotics and controls respectively,  $p=0.002$ ) (21). Muscle biopsies in cirrhotics have also demonstrated significantly increased myostatin expression compared to controls (22).

Although elevated myostatin levels may make an important contribution to sarcopenia in cirrhosis, the cause is uncertain. One possible mechanism is that ammonia levels are frequently elevated in cirrhosis, and that this increases myostatin expression. In a murine cirrhotic model, ammonia (administered via intraperitoneal injection) was shown to stimulate myostatin expression in muscle via the activation of the transcription factor nuclear factor kappa beta (23). Furthermore in this model, muscle wasting was induced by ammonia in wild-type but not myostatin knock-out mice and there was a positive correlation between serum ammonia and myostatin expression.

The reduction in serum testosterone levels and IGF-1 levels in cirrhosis (24, 25) likely also contribute to elevated myostatin levels since these mediators normally act to suppress myostatin expression (26, 27). The possible relationship between myostatin and other stimulators of muscle differentiation is represented in Figure 1.

### Altered metabolism - abnormal use of protein as an energy source

The metabolic alterations in cirrhosis are far more complex than simple malnutrition and reduction in muscle protein production. Cirrhosis mimics the state of starvation, with inappropriate use of body fat and protein stores for gluconeogenesis. This proteolysis and lipolysis can occur even during short periods of fasting such as overnight, which should not happen under normal physiological conditions. This switch to the use of fat and protein as an energy source is thought to be due to a reduction in hepatic glycogen stores which results in a need to generate glucose from alternate sources (28).

One study demonstrated that energy use derived from carbohydrate during a 12 hour overnight fast was only 13% in cirrhotics compared to 39% in normal subjects (29). In controls at least 36 hrs of fasting was required for the proportion of calorie production from fat and protein to approach that in overnight fasted cirrhotics. Several other studies have documented increased ketogenesis and amino acid consumption in cirrhosis (5, 30, 31) and respiratory quotient (carbon dioxide production as compared to oxygen consumption) has been shown to be reduced in cirrhosis ( $0.63 \pm 0.05$  vs  $0.84 \pm 0.06$  in controls,  $p < 0.001$ ), which again reflects a lower proportion of energy derived from carbohydrate (32).

In keeping with these findings, whole body protein turnover was found to be increased from  $1.8 \pm 0.3$ g of lean body mass per 9 hours to  $3.14 \pm 1.2$ g of lean body mass per 9 hours in cirrhotics (30). The consumption of body fat and protein stores in cirrhotics is likely further exacerbated by an overall increase in resting energy expenditure, in part driven by the chronic upregulation of inflammatory mediators (33). This metabolic switch to the use of amino acids to create glucose results in reduced levels of circulating branched chain amino acids (BCAAs) in patients with cirrhosis (34). This may further compound muscle breakdown since BCAAs are the preferential energy source of skeletal muscle and muscle tissue (35).

### Relationship between hepatic encephalopathy and muscle mass

A recent prospective study identified a significant correlation between the presence of hepatic encephalopathy and sarcopenia in cirrhosis. The prevalence of sarcopenia was found to be 30% in patients without encephalopathy, 49% with minimal change encephalopathy and 56% with overt encephalopathy (36). This may reflect a causative relationship between these two common sequelae of cirrhosis (7). Although BCAAs are utilised for energy production in

cirrhosis, the main cause for reduced BCAA levels is their uptake by muscle to assist in ammonia detoxification via glutamine synthase (37). Muscle uptake of BCAAs is significantly higher in cirrhotics than controls (32 vs -12 $\mu$ mol/L blood) and leads to a reduced BCAA/aromatic amino acid ratio (1.65 vs 2.73,  $p < 0.05$ ) (34). Thus in sarcopenic cirrhotic patients, both reduced circulating BCAA levels and reduced muscle mass may contribute to impaired ammonia clearance. A Cochrane review has concluded the BCAA therapy has a beneficial effect on hepatic encephalopathy (RR 0.76, 95% CI 0.63 to 0.92) which reflects the important role BCAAs play in ammonia clearance (38) but few studies investigate the impact of BCAAs on muscle mass.

#### Activation of the Ubiquitin Proteasome Pathway (UPP) and Autophagy - increased muscle breakdown

A review of 21 studies examining sarcopenia of ageing concluded a strong link exists between inflammation and sarcopenia, with TNF-alpha and IL6 most commonly implicated, with some of these studies reporting muscle biopsy data that suggests the mechanism is related oxidative stress (39). Cirrhosis is a pro-inflammatory state, in which levels of TNF-alpha and other inflammatory mediators such as interleukin-1 and interleukin-6 are elevated (40). In experimental cirrhosis a strong correlation was demonstrated between muscle TNF-alpha and muscle ubiquitin levels ( $r = 0.86$ ,  $p < 0.001$ ), which reflects the activation of the UPP, suggesting that in cirrhosis, inflammation may also contribute to sarcopenia (41). A recent murine study showed that ethanol can stimulate muscle autophagy without altering proteasome activity or the UPP (13), indicating that alcohol induced autophagy may directly contribute to sarcopenia in patients with alcoholic liver disease.

#### Hormone deficiency

In men, testosterone levels correlate with muscle mass across low to supra-physiological levels (42). This hormone has dual positive effects in muscle, by both inhibiting myostatin production (26) which leads to less inhibition of satellite cell activity, and increasing IGF-1 levels (43), mTOR activation and muscle protein synthesis (43). Up to 90% of men with cirrhosis have low testosterone levels, due to defects at all levels of the hypothalamic-pituitary-testicular axis (44, 45). In addition, SHBG is often elevated, which strongly binds testosterone and can thereby lead to an even greater reduction in free testosterone (25). The



possibility that low testosterone levels contribute to sarcopenia in men with cirrhosis is supported by a recent study which demonstrated a correlation between testosterone levels, sarcopenia and overall mortality ( $p=0.019$ ) (4).

IGF-1 levels are reported to be low in cirrhosis (24) which would be expected to result in reduced mTOR-mediated activation of muscle protein synthesis and increased myostatin levels (27). Although a relationship has been established between falling IGF-1 and the sarcopenia of ageing (46), a similar relationship has not been established in cirrhosis. In one study, no correlation between IGF-1 and muscle mass was found in a cohort of 64 hospitalised cirrhotics, however this may be due to the effect of acute illness on IGF-1 levels(47). Thus, although a link between reduced IGF-1 levels in cirrhosis and sarcopenia is scientifically plausible, this requires further study.

## **Diagnosis of sarcopenia**

### *Clinical features and functional measures*

#### Anthropometry

Body mass index can be a poor indicator of nutritional status in patients with cirrhosis as it can be falsely elevated due to fluid overload in the context of portal hypertension (48) and also cannot differentiate fat mass from muscle mass. Therefore we do not recommend the use of such techniques.

#### Hand grip strength

Hand grip strength is an objective measure of functional muscle strength of the hand and forearm. This conveys important information that could potentially translate to the capacity for physical activity which is not necessarily captured by muscle mass quantification. It correlates modestly with muscle thickness of the hand and forearm (correl 0.379,  $p = 0.001$  in men and correl 0.268,  $p = 0.002$  in women) (49). It is interesting to note that some studies, particularly in the elderly, show that it is possible to stimulate an increase in muscle mass without necessarily demonstrating an increase in strength or physical activity (50). Handgrip strength has been shown in a large population study of >140,000 healthy adults to be independently correlated with all-cause mortality (hazard ratio per 5 kg reduction in grip strength of 1.16 (CI 1.13–1.20),  $p<0.0001$ ) (51).

## Frailty

In the general population functional measures of frailty are powerful predictors of mortality. For example, in a study of elderly patients, failure to complete the 6 minute walk test, was the best predictor of mortality with a hazard ratio for mortality of 3.26 (CI 1.38-7.69) (52). The advantages of such measures are their ability to be repeated serially in outpatient settings as well as their non-invasiveness. Limitations include subjective components and difficulty in standardisation.

Measures of frailty derived from geriatric populations have been applied to patients on the waitlist for liver transplantation, where they have also been shown to have prognostic value. These include the 6 minute walk test (frail defined as <250m), the Fried frailty index (FFI) (frail defined as  $\geq 3$  out of 5 points), and the short physical performance battery (SPPB) (frail defined as a SPPB score of <9 out of 15) (53, 54).

### *Quantitative investigations.*

Low serum albumin may be an indicator of protein malnutrition but can also be reduced in the context of cirrhosis due to hepatic synthetic dysfunction. Older quantitative investigative techniques used to assess muscle mass included urinary creatinine excretion or underwater weighing which have suboptimal accuracy and provide limited information. Other more experimental techniques include neutron activation analysis and air displacement plethysmography which are highly accurate but not practical in the clinical setting (55). There are however techniques that can be performed within a normal hospital setting using easily accessible methods.

## MRI

Magnetic Resonance Imaging (MRI) provides high resolution three dimensional images which can accurately differentiate tissue planes. Volume calculations can subsequently be performed to create a complete body composition model for the entire body in a single scan. MRI has been used for research purposes to accurately display differences in muscle composition between men and women, and loss of lower limb muscle mass with ageing. It is thought to be highly accurate and no ionising radiation exposure is required (56). Limitations of this technique include high cost and limited access and this has precluded its use in routine clinical practice.

## CT

Computerised Tomography (CT) is also able to differentiate muscle from other body tissues, and create a three dimensional model similar to MRI. It is quick, relatively cheap, readily available and provides a high degree of accuracy. However whole body CT scanning exposes patients to unacceptably high ionising radiation levels which have been linked to increased rates of subsequent malignancy (57, 58). Therefore whole body CT is not an acceptable tool for routine and repeated quantification of body composition.

Assessment of thickness of the psoas muscle on CT scan has been employed as an estimate of muscle mass (59). However skeletal muscle area derived from a single slice CT has become more easily reproducible, and reduces the radiation exposure required to only 2.6 millisieverts. Measuring cross sectional muscle area at either the level of the third (L3) or fourth (L4) lumbar vertebrae has been shown to correlate well with total body muscle mass ( $r=0.71$ ), and it is now accepted as a safe and accurate means of estimating muscle mass (60). When adjusted for patient height to take stature into account it is referred to as skeletal muscle index (61).

L3 skeletal muscle index has been shown to be of higher accuracy in the diagnosis of sarcopenia in cirrhosis than anthropometry or DEXA scanning (62) and is now the most commonly employed method in studies investigating sarcopenia in cirrhosis (61, 63). Diagnostic criteria have been extrapolated from oncology populations, where sarcopenia is defined as  $<38.5\text{cm}^2$  for women and  $<52.4\text{cm}^2$  for men (64). Multiple studies in cirrhosis which have employed this definition have produced clinically meaningful results and it is increasingly accepted as the most appropriate definition of sarcopenia when using cross sectional imaging (3, 61, 65, 66).

#### Dual-Energy X-ray Absorptiometry (DEXA)

DEXA scanning uses multiple low dose X-rays to create a 3 dimensional compartmental model which is highly accurate at differentiating fat, fat-free mass and bone mineral mass. It has been shown to correlate well with gold standard experimental techniques such as neutron activation analysis (55). A frequently used measure to assess functional muscle is appendicular lean mass (APLM), which specifically quantifies arm and leg lean mass. APLM has been shown to correlate well with total body muscle mass as measured by whole body MRI (67). Sarcopenia has been defined as an APLM index ( $\text{APLM}/\text{height}^2$ ) of  $\geq 2$  standard deviations below the mean, which for a caucasian 40 year-old corresponds to an APLM index of  $<4.61\text{kg}/\text{m}^2$  in women and  $<6.57\text{kg}/\text{m}^2$  in men (68).

DEXA has been evaluated in patients with cirrhosis of varying aetiologies and severities. Neutron activation analysis was again used as a gold standard, and DEXA was shown to provide accurate estimations of fat-free mass and fat mass. (69) The APLM skeletal muscle index has also been employed to examine contributing factors to sarcopenia in cirrhotic patients (14). The major limitation of DEXA is its inability to differentiate water from muscle. As a result, oedematous tissue can falsely elevate muscle mass readings (70) which is a potential concern in cirrhotics though confounding by ascites is removed by the use of APLM (37).

A major benefit of DEXA is that it is cheap and readily available. In addition, the very low dose of radiation per examination makes it safe to be used for serial measurements. Given its safety, proven accuracy and reproducibility, we believe DEXA-measured APLM is likely to be the most appropriate diagnostic tool to monitor response to intervention in future trials in cirrhosis.

## **Implications**

### *Pre-transplant mortality*

The prognostic importance of sarcopenia in cirrhosis is becoming well recognised with multiple reports that it is associated with mortality independent of the MELD score, the tool most widely used to predict prognosis in patients awaiting liver transplantation (3, 4, 59, 61, 63, 66). A summary of some of the key studies investigating the impact of sarcopenia on mortality are represented in Table 1.

As in geriatric populations, functional measures of frailty have been associated with survival in cirrhosis, independent of the MELD score. Each 100 metre reduction in the 6 minute walk test in one cohort of cirrhotics was independently associated with reduced survival (HR 0.48) (53). In a large pre-transplant cohort, each increase by one point in the FFI score was associated with 45% increase in mortality, and each reduction by one point in the SPPB score correlated with a 19% increase in mortality (54). Reduced grip strength ( $\geq 2$  standard deviations below the mean) has been associated with 20.7% 12 month mortality as compared to 0% mortality in those with higher readings ( $p < 0.05$ ) (71).

Mortality has been demonstrated to be from 2.3 to 5.4 times higher in patients meeting diagnostic criteria for sarcopenia as compared to those without, independent of the MELD

score (Table 1). In addition, there is evidence that a rapid rate of decline in muscle mass predicts mortality, with a hazard ratio for mortality on multivariable analysis of 2.73 [95% Ci 1.43-5.44] in patients with >3.1% change in skeletal muscle index per year as compared to less dramatic muscle loss (72).

The utility of sarcopenia as a predictor of outcomes has been assessed by the incorporation of L3 skeletal muscle index on CT scan into a MELD score model to assess prognosis in a study in of 669 cirrhotic patients. The MELD-sarcopenia model had improved predictive value for 12 month mortality compared to the MELD score alone (c statistic 0.77 vs 0.73,  $p=0.03$ ) and was particularly useful in patients with MELD score <15 (c statistic 0.85 vs. 0.69,  $p=0.02$ ) (73). Validation is required in other studies. This should include investigation of the post-transplant outcomes of sarcopenic patients since this may facilitate allocation of organs to patients who will gain most benefit, and help identify a sarcopenic threshold below which transplantation is likely to be futile.

Although sarcopenia is associated with increased mortality, there is evidence to suggest that its reversal improves survival. In a study of trans-jugular intrahepatic portosystemic shunts (TIPS) outcomes, muscle mass improved post-TIPS in 41 of 57 patients. The 12 month mortality of patients with reversal of sarcopenia was 9.8% vs 43.5% in those in whom sarcopenia persisted ( $p=0.007$ ) (74). This highlights the importance of identifying strategies for improving muscle mass in this patient group.

### *Infection risk*

In both pre and post-transplant populations, sarcopenia has been associated with increased infection risk. An early study employing L3 SMI to quantify muscle mass showed that the increase in mortality associated with sarcopenia was attributable to an increase in sepsis-related deaths (61). An earlier study investigating the impact of mid-arm circumference demonstrated increased infection risk in those below the 25<sup>th</sup> percentile as compared to those above (32% vs 8%,  $p=0.02$ ) (75).

In the post-liver transplant setting, infection risk was found to be 4-fold higher in patients with the lowest quartile of muscle mass compared with the highest quartile (76). Sarcopenia in the elderly has also been associated with increased infection risk (RR 2.1) (77). This may explain the association between sarcopenia and mortality in cirrhosis, given this population is already at particularly high risk of sepsis-related death (78).

### *Post-transplant outcome*

Sarcopenia has also been linked with poorer post-transplant outcomes, including increased length of stay and reduced survival, and thus prioritization of patients on the basis of sarcopenia may not be an appropriate strategy. In male transplant recipients, each 10% incremental increase in muscle mass was associated with a 9% shorter length of stay, and a 12% shorter ICU stay. Each one unit decrease in L3 SMI resulted in a 5% increase in risk of death (65).

### *Quality of life*

In addition to its effects on mortality, sarcopenia likely contributes to reduced quality of life in cirrhosis. Muscle weakness limits exercise capability, can profoundly impact simple activities of daily living and may also contribute to fatigue. These effects can severely impact participation in the community, family and workforce. Altered muscle physiology is also thought to contribute to muscle cramps which are common in cirrhosis and have been identified as a major factor affecting quality of life (79, 80).

### *Metabolic function*

Sarcopenia itself can also lead to secondary alterations in metabolic function that may further contribute to the progression of liver disease. Muscle is a highly metabolically active tissue that contributes significantly to insulin-mediated glucose uptake (81). As a result, sarcopenia reduces glucose uptake and increases insulin resistance, which has been associated with accelerated progression of liver fibrosis and the development of hepatocellular carcinoma (82, 83). Healthy muscle also secretes biologically active mediators known as myokines, which have a range of effects including mediation of inflammation (84). Sarcopenia may therefore potentiate the pro-inflammatory state of cirrhosis which itself can lead to further reductions in muscle mass.

### *Significance in men versus women*

Data in both pre and post-transplant populations have suggested the prognostic impact of sarcopenia in cirrhosis is more marked in men (61, 65). The reason for the stronger association in men has not been studied, but it could potentially relate to a reduction in testosterone levels.

### **Potential therapeutic interventions**

Potential treatment options, mechanisms of action and supporting evidence are presented in Table 2.

### Diet

Simply increasing caloric intake does not prevent the development of sarcopenia in cirrhosis (85). However there is evidence to suggest that a high energy, high protein (HEHP) diet can improve nitrogen retention (4.3 +/-3.2g of nitrogen/day on HEHP as compared to -2.2 +/-1.9g of nitrogen/day when fasting,  $p<0.01$ ) (30). A late evening snack has also been shown to improve nitrogen balance in end-stage cirrhosis compared to usual diet (5.53 +/-0.53g/day vs 3.57 +/-0.78 g/day,  $p<0.01$ ), which acts to minimise the exaggerated starvation response that occurs during overnight fasting (28). Dietary interventions should therefore routinely incorporate adequate protein intake and the consumption of a long-acting energy source including complex carbohydrates in the late evening.

Given that BCAA levels are low in cirrhosis, the potential therapeutic role of leucine supplementation has been investigated. This theoretically provides an energy substrate for muscle as well as stimulating muscle protein synthesis via activation of the mTOR pathway. One small trial demonstrated significantly reduced autophagy and improved mTOR signalling in human muscle following administration of leucine, and this was associated with increased muscle protein synthesis (22). Activation of the mTOR pathway was also increased by BCAA administration in an animal model of cirrhosis (11). A recent Cochrane review concluded that BCAA administration improves clinically apparent hepatic encephalopathy (38), however randomised controlled trials of BCAA therapy specifically assessing muscle mass in cirrhotic subjects are lacking.

### Exercise

Although there is evidence suggesting that lack of physical activity is associated with sarcopenia and worse outcomes in patients with cirrhosis (86), there is no specific evidence that physical therapy can reverse sarcopenia in this setting. However it seems reasonable to suggest that gentle physical therapy may help prevent further muscle loss and maintain physical function. It is still unclear if resistance or cardiovascular training is most effective, but in studies in sarcopenia of ageing, any physical exercise program has benefit compared to placebo (87). It should be noted that the nutritional effects of physical therapy need to be monitored given that increased energy expenditure may accelerate protein catabolism. If

tolerated, we recommend walking 30-40 minutes 3 to 4 times per week, and lifting light weights such as hand weights 2 to 3 times per week.

### Drug therapies

Given the known alteration in myostatin levels in cirrhosis, myostatin blockers have been proposed as a potential treatment for sarcopenia in this setting. A recent phase 2 trial in frail older patients has reported that a humanised monoclonal anti-myostatin antibody increases appendicular lean mass (+0.43 kg (CI 0.19-0.66) on active treatment,  $p < 0.001$ ) as well as increases gait speed (+0.05m/s,  $p = 0.088$ ) (88) but there are no human trials in cirrhotics.

IGF-1 has been shown to improve nitrogen retention in cirrhotic rats (89), as well as reduce myostatin and increase muscle mass (90) however randomised trials in humans have not yet been performed. The effects of testosterone therapy on muscle have not been extensively evaluated in men with cirrhosis, however one small uncontrolled trial showed an improvement in hand-grip strength with topical testosterone therapy (34.0kg at baseline as compared to 39.2kg post-treatment,  $p < 0.001$ ) (91).

Therapies used to treat hepatic encephalopathy such as lactulose and rifaximin reduce ammonia levels. Given that ammonia consumes BCAAs in muscle as well as activates myostatin, these therapies could potentially have beneficial effects on muscle mass, but this has not been investigated.

### Reversal of portal HTN

As outlined above, one uncontrolled study demonstrated an increase in muscle mass and an associated improvement in prognosis following successful TIPS placement. Psoas muscle area improved in 70% of patients with an increase of the mean area from 22.8 cm<sup>2</sup> at baseline to 25.1cm<sup>2</sup> post-TIPS ( $p < 0.001$ ). (74). This improvement could relate to a reduction in portal pressure, however many other factors such as reduced ascites, reduced metabolic rate, increased appetite and improved nutrition could have contributed to this effect. This intriguing finding requires validation in a well-designed randomised controlled trial.

### Liver Transplantation



Liver transplantation is the definitive treatment for advanced cirrhosis and its complications. Few studies have specifically investigated the effect of transplantation on muscle mass and the available data are conflicting. Many of contributors to sarcopenia are removed by transplantation, with the restoration of normal hepatocyte function and portal pressure, however immunosuppressive medications such as corticosteroids, calcineurin inhibitors and mTOR inhibitors are all known to adversely affect muscle mass. Published data suggest that muscle mass can stabilise, increase or decrease after liver transplantation (92, 93). Clearly further investigation and longer term studies are required to better clarify this issue.

## Conclusion

Sarcopenia is one of the most commonly encountered features of cirrhosis and is associated with significant morbidity and mortality. The classic teaching that this condition responds to a high protein diet and exercise ignores the complex metabolic alterations in cirrhosis that contribute to muscle loss. With increasing understanding of the pathogenesis of sarcopenia in this population, we are moving closer to developing treatments that targets specific changes in energy requirements, metabolic pathways, hormonal abnormalities and nutritional deficiencies.

## Figures

Figure 1. Muscle regulation and potential therapeutic strategies

Legend:

IGF-1: insulin-like growth factor 1, PKB/AKT: protein kinase B, mTOR: mammalian target of rapamycin, FOXO: forkhead box transcription factor

Solid arrows indicate activating pathways

Dashed lines indicate inhibitory pathways

**Bold\*** indicates potential therapeutic intervention for sarcopenia

*Italics/shaded background* indicate modifiable negative regulators of muscle mass

This article is protected by copyright. All rights reserved

Figure 2. Overview of the causes of sarcopenia in cirrhosis

BCAAs: branched chain amino acids

**Bold\*** indicates potentially modifiable components

## References

1. Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The Epidemiology of Cirrhosis in the United States: A Population-based Study. *Journal of clinical gastroenterology*. 2014. Epub 2014/10/08.
2. Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2014;20(6):640-8. Epub 2014/03/29.
3. Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. *Nutrition*. 2015;31(1):193-9. Epub 2014/12/03.
4. Sinclair M, Grossmann M, Angus PW, Hoermann R, Hey P, Scodellaro T, et al. Low testosterone is a better predictor of mortality than sarcopenia in men with advanced liver disease. *Journal of gastroenterology and hepatology*. 2015. Epub 2015/09/29.
5. Dasarathy S. Consilience in sarcopenia of cirrhosis. *Journal Of Cachexia, Sarcopenia And Muscle*. 2012;3(4):225-37.
6. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. *Journal of gastroenterology and hepatology*. 2001;16(5):531-5. Epub 2001/05/15.
7. Kalaitzakis E, Josefsson A, Castedal M, Henfridsson P, Bengtsson M, Andersson B, et al. Hepatic encephalopathy is related to anemia and fat-free mass depletion in liver transplant candidates with cirrhosis. *Scandinavian journal of gastroenterology*. 2013;48(5):577-84. Epub 2013/03/05.

8. Bryant RV, Ooi S, Schultz CG, Goess C, Grafton R, Hughes J, et al. Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. *Alimentary pharmacology & therapeutics*. 2015;41(9):895-906. Epub 2015/03/11.
9. Drummond MJ, Dreyer HC, Fry CS, Glynn EL, Rasmussen BB. Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling. *J Appl Physiol* (1985). 2009;106(4):1374-84. Epub 2009/01/20.
10. Bamman MM, Shipp JR, Jiang J, Gower BA, Hunter GR, Goodman A, et al. Mechanical load increases muscle IGF-I and androgen receptor mRNA concentrations in humans. *American journal of physiology Endocrinology and metabolism*. 2001;280(3):E383-90. Epub 2001/02/15.
11. Matsumura T, Morinaga Y, Fujitani S, Takehana K, Nishitani S, Sonaka I. Oral administration of branched-chain amino acids activates the mTOR signal in cirrhotic rat liver. *Hepatology research : the official journal of the Japan Society of Hepatology*. 2005;33(1):27-32. Epub 2005/09/20.
12. Frost RA, Lang CH. Multifaceted role of insulin-like growth factors and mammalian target of rapamycin in skeletal muscle. *Endocrinology and metabolism clinics of North America*. 2012;41(2):297-322, vi. Epub 2012/06/12.
13. Thapaliya S, Runkana A, McMullen MR, Nagy LE, McDonald C, Naga Prasad SV, et al. Alcohol-induced autophagy contributes to loss in skeletal muscle mass. *Autophagy*. 2014;10(4):677-90. Epub 2014/02/05.
14. Hayashi F, Matsumoto Y, Momoki C, Yuikawa M, Okada G, Hamakawa E, et al. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. *Hepatology research : the official journal of the Japan Society of Hepatology*. 2013;43(12):1264-75. Epub 2013/03/16.
15. Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG. Malnutrition in end stage liver disease: recommendations and nutritional support. *Journal of gastroenterology and hepatology*. 2008;23(4):527-33. Epub 2008/04/10.
16. Madden AM, Bradbury W, Morgan MY. Taste perception in cirrhosis: its relationship to circulating micronutrients and food preferences. *Hepatology*. 1997;26(1):40-8. Epub 1997/07/01.
17. Romiti A, Merli M, Martorano M, Parrilli G, Martino F, Riggio O, et al. Malabsorption and nutritional abnormalities in patients with liver cirrhosis. *The Italian journal of gastroenterology*. 1990;22(3):118-23. Epub 1990/06/01.
18. Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. *Pathophysiological and clinical implications*. *Journal of hepatology*. 2013;58(5):1020-7. Epub 2012/11/28.
19. White TA, LeBrasseur NK. Myostatin and sarcopenia: opportunities and challenges - a mini-review. *Gerontology*. 2014;60(4):289-93. Epub 2014/01/25.

20. Siriatt V, Salerno MS, Berry C, Nicholas G, Bower R, Kambadur R, et al. Antagonism of myostatin enhances muscle regeneration during sarcopenia. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2007;15(8):1463-70. Epub 2007/06/07.
21. Garcia PS, Cabbabe A, Kambadur R, Nicholas G, Csete M. Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. *Anesthesia and analgesia*. 2010;111(3):707-9. Epub 2010/08/06.
22. Tsien C, Davuluri G, Singh D, Allawy A, Ten Have GA, Thapaliya S, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. *Hepatology*. 2015;61(6):2018-29. Epub 2015/01/24.
23. Qiu J, Thapaliya S, Runkana A, Yang Y, Tsien C, Mohan ML, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(45):18162-7. Epub 2013/10/23.
24. Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. *Journal of hepatology*. 2008;49(1):34-42. Epub 2008/05/06.
25. Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Scholmerich J, et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. *European journal of gastroenterology & hepatology*. 2003;15(5):495-501. Epub 2003/04/19.
26. Kovacheva EL, Hikim AP, Shen R, Sinha I, Sinha-Hikim I. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. *Endocrinology*. 2010;151(2):628-38. Epub 2009/12/22.
27. Valdes JA, Flores S, Fuentes EN, Osorio-Fuentealba C, Jaimovich E, Molina A. IGF-1 induces IP3 -dependent calcium signal involved in the regulation of myostatin gene expression mediated by NFAT during myoblast differentiation. *Journal of cellular physiology*. 2013;228(7):1452-63. Epub 2012/12/21.
28. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. *Journal of gastroenterology and hepatology*. 2012;27(3):430-41.
29. Owen OE, Trapp VE, Reichard GA, Jr., Mozzoli MA, Moctezuma J, Paul P, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. *The Journal of clinical investigation*. 1983;72(5):1821-32. Epub 1983/11/01.

30. Dichi JB, Dichi I, Maio R, Correa CR, Angeleli AY, Bicudo MH, et al. Whole-body protein turnover in malnourished patients with child class B and C cirrhosis on diets low to high in protein energy. *Nutrition*. 2001;17(3):239-42. Epub 2001/04/20.
31. Morrison WL, Bouchier IA, Gibson JN, Rennie MJ. Skeletal muscle and whole-body protein turnover in cirrhosis. *Clinical science*. 1990;78(6):613-9. Epub 1990/06/01.
32. Glass C, Hipskind P, Tsien C, Malin SK, Kasumov T, Shah SN, et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study. *Journal of Applied Physiology*. 2013;114(3):559-65.
33. Muller MJ, Bottcher J, Selberg O, Weselmann S, Boker KH, Schwarze M, et al. Hypermetabolism in clinically stable patients with liver cirrhosis. *The American journal of clinical nutrition*. 1999;69(6):1194-201. Epub 1999/06/05.
34. Dam G, Sorensen M, Buhl M, Sandahl TD, Moller N, Ott P, et al. Muscle metabolism and whole blood amino acid profile in patients with liver disease. *Scandinavian journal of clinical and laboratory investigation*. 2015;75(8):674-80. Epub 2015/08/06.
35. Dejong CH, van de Poll MC, Soeters PB, Jalan R, Olde Damink SW. Aromatic amino acid metabolism during liver failure. *The Journal of nutrition*. 2007;137(6 Suppl 1):1579S-85S; discussion 97S-98S. Epub 2007/05/22.
36. Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. *Metabolic brain disease*. 2013;28(2):281-4. Epub 2012/12/12.
37. Holecek M. Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. *Nutrition*. 2015;31(1):14-20. Epub 2014/09/16.
38. Gluud LL, Dam G, Les I, Cordoba J, Marchesini G, Borre M, et al. Branched-chain amino acids for people with hepatic encephalopathy. *Cochrane Database Syst Rev*. 2015;9:CD001939. Epub 2015/09/18.
39. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. *Current opinion in clinical nutrition and metabolic care*. 2012;15(1):12-22. Epub 2011/11/24.
40. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. *Gastroenterology*. 1992;103(1):264-74. Epub 1992/07/01.
41. Lin SY, Chen WY, Lee FY, Huang CJ, Sheu WH. Activation of ubiquitin-proteasome pathway is involved in skeletal muscle wasting in a rat model with biliary cirrhosis: potential role of TNF-alpha. *American journal of physiology Endocrinology and metabolism*. 2005;288(3):E493-501. Epub 2004/11/04.

42. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. *American journal of physiology Endocrinology and metabolism*. 2001;281(6):E1172-81. Epub 2001/11/10.
43. Ibebunjo C, Eash JK, Li C, Ma Q, Glass DJ. Voluntary running, skeletal muscle gene expression, and signaling inversely regulated by orchidectomy and testosterone replacement. *American journal of physiology Endocrinology and metabolism*. 2011;300(2):E327-40. Epub 2010/11/04.
44. Handelsman DJ, Strasser S, McDonald JA, Conway AJ, McCaughan GW. Hypothalamic-pituitary-testicular function in end-stage non-alcoholic liver disease before and after liver transplantation. *Clinical endocrinology*. 1995;43(3):331-7. Epub 1995/09/01.
45. Grossmann M, Hoermann R, Gani L, Chan I, Cheung A, Gow PJ, et al. Low testosterone levels as an independent predictor of mortality in men with chronic liver disease. *Clinical endocrinology*. 2012;77(2):323-8. Epub 2012/01/28.
46. Giovannini S, Marzetti E, Borst SE, Leeuwenburgh C. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. *Mechanisms of ageing and development*. 2008;129(10):593-601. Epub 2008/09/03.
47. Caregaro L, Alberino F, Amodio P, Merkel C, Angeli P, Plebani M, et al. Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. *Nutrition*. 1997;13(3):185-90. Epub 1997/03/01.
48. Loguercio C, Sava E, Marmo R, del Vecchio Blanco C, Coltorti M. Malnutrition in cirrhotic patients: anthropometric measurements as a method of assessing nutritional status. *The British journal of clinical practice*. 1990;44(3):98-101. Epub 1990/03/01.
49. Abe T, Counts BR, Barnett BE, Dankel SJ, Lee K, Loenneke JP. Associations between Handgrip Strength and Ultrasound-Measured Muscle Thickness of the Hand and Forearm in Young Men and Women. *Ultrasound in medicine & biology*. 2015. Epub 2015/05/12.
50. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. *Therapeutics and clinical risk management*. 2009;5(3):427-48. Epub 2009/08/27.
51. Leong D, Teo K, Rangarajan S. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. *The Lancet*. 2015;online 13 May 2015.
52. Martin-Ponce E, Hernandez-Betancor I, Gonzalez-Reimers E, Hernandez-Luis R, Martinez-Riera A, Santolaria F. Prognostic value of physical function tests: hand grip strength and six-minute walking test in elderly hospitalized patients. *Scientific reports*. 2014;4:7530. Epub 2014/12/23.
53. Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, et al. Six-minute walk distance predicts mortality in liver transplant candidates. *Liver transplantation : official publication of the*

American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2010;16(12):1373-8. Epub 2010/12/01.

54. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2014;14(8):1870-9. Epub 2014/06/18.

55. Wilson JP, Strauss BJ, Fan B, Duewer FW, Shepherd JA. Improved 4-compartment body-composition model for a clinically accessible measure of total body protein. *The American journal of clinical nutrition*. 2013;97(3):497-504. Epub 2013/02/01.

56. Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. *J Appl Physiol (1985)*. 2000;89(1):81-8. Epub 2000/07/25.

57. Badawy MK, Galea M, Mong KS, U P. Computed tomography overexposure as a consequence of extended scan length. *Journal of medical imaging and radiation oncology*. 2015. Epub 2015/07/16.

58. Brenner DJ, Elliston CD. Estimated radiation risks potentially associated with full-body CT screening. *Radiology*. 2004;232(3):735-8. Epub 2004/07/27.

59. Durand F, Buyse S, Francoz C, Laouenan C, Bruno O, Belghiti J, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. *Journal of hepatology*. 2014;60(6):1151-7. Epub 2014/03/13.

60. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. *J Appl Physiol (1985)*. 2004;97(6):2333-8. Epub 2004/08/18.

61. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2012;10(2):166-73, 73 e1. Epub 2011/09/07.

62. Giusto M, Lattanzi B, Albanese C, Galtieri A, Farcomeni A, Giannelli V, et al. Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. *European journal of gastroenterology & hepatology*. 2015;27(3):328-34. Epub 2015/01/09.

63. Kim TY, Kim MY, Sohn JH, Kim SM, Ryu JA, Lim S, et al. Sarcopenia as a useful predictor for long-term mortality in cirrhotic patients with ascites. *Journal of Korean medical science*. 2014;29(9):1253-9. Epub 2014/09/24.

64. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and

gastrointestinal tracts: a population-based study. *The Lancet Oncology*. 2008;9(7):629-35. Epub 2008/06/10.

65. DiMartini A, Cruz RJ, Jr., Dew MA, Myaskovsky L, Goodpaster B, Fox K, et al. Muscle mass predicts outcomes following liver transplantation. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2013;19(11):1172-80. Epub 2013/08/21.

66. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. *Liver Transplantation: Official Publication Of The American Association For The Study Of Liver Diseases And The International Liver Transplantation Society*. 2012;18(10):1209-16.

67. Kim J, Wang Z, Heymsfield SB, Baumgartner RN, Gallagher D. Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. *The American journal of clinical nutrition*. 2002;76(2):378-83. Epub 2002/07/30.

68. Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. *PloS one*. 2009;4(9):e7038. Epub 2009/09/16.

69. Strauss BJ, Gibson PR, Stroud DB, Borovnicar DJ, Xiong DW, Keogh J. Total body dual X-ray absorptiometry is a good measure of both fat mass and fat-free mass in liver cirrhosis compared to "gold-standard" techniques. Melbourne Liver Group. *Annals of the New York Academy of Sciences*. 2000;904:55-62. Epub 2000/06/24.

70. Proctor DN, O'Brien PC, Atkinson EJ, Nair KS. Comparison of techniques to estimate total body skeletal muscle mass in people of different age groups. *The American journal of physiology*. 1999;277(3 Pt 1):E489-95. Epub 1999/09/14.

71. Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. *Nutrition*. 2005;21(2):113-7. Epub 2005/02/23.

72. Hanai T, Shiraki M, Ohnishi S, Miyazaki T, Ideta T, Kochi T, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. *Hepatology research : the official journal of the Japan Society of Hepatology*. 2015. Epub 2015/11/19.

73. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JX, et al. Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis. *Clinical and translational gastroenterology*. 2015;6:e102. Epub 2015/07/17.

74. Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. *European journal of gastroenterology & hepatology*. 2013;25(1):85-93. Epub 2012/09/27.



75. Harrison J, McKiernan J, Neuberger JM. A prospective study on the effect of recipient nutritional status on outcome in liver transplantation. *Transplant international : official journal of the European Society for Organ Transplantation*. 1997;10(5):369-74. Epub 1997/01/01.
76. Krell RW, Kaul DR, Martin AR, Englesbe MJ, Sonnenday CJ, Cai S, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2013;19(12):1396-402. Epub 2013/10/24.
77. Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S. Sarcopenia is predictive of nosocomial infection in care of the elderly. *The British journal of nutrition*. 2006;96(5):895-901. Epub 2006/11/10.
78. Fernandez J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. *Hepatology*. 2012;55(5):1551-61. Epub 2011/12/21.
79. Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. *Gastroenterology*. 2001;120(1):170-8. Epub 2001/02/24.
80. Mehta SS, Fallon MB. Muscle cramps in liver disease. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2013;11(11):1385-91; quiz e80. Epub 2013/04/02.
81. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. *The lancet Diabetes & endocrinology*. 2014;2(10):819-29. Epub 2014/04/16.
82. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. *World journal of gastroenterology : WJG*. 2010;16(18):2265-71. Epub 2010/05/12.
83. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. *The American journal of gastroenterology*. 2005;100(7):1509-15. Epub 2005/06/30.
84. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. *Nature reviews Endocrinology*. 2012;8(8):457-65. Epub 2012/04/05.
85. Campillo B, Bories PN, Pornin B, Devanlay M. Influence of liver failure, ascites, and energy expenditure on the response to oral nutrition in alcoholic liver cirrhosis. *Nutrition*. 1997;13(7-8):613-21. Epub 1997/07/01.

86. Toshikuni N, Arisawa T, Tsutsumi M. Nutrition and exercise in the management of liver cirrhosis. *World journal of gastroenterology : WJG*. 2014;20(23):7286-97. Epub 2014/06/27.
87. Cruz-Jentoft AJ, Landi F, Schneider SM, Zuniga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age and ageing*. 2014;43(6):748-59. Epub 2014/09/23.
88. Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. *The lancet Diabetes & endocrinology*. 2015;3(12):948-57. Epub 2015/10/31.
89. Picardi A, de Oliveira AC, Muguerza B, Tosar A, Quiroga J, Castilla-Cortazar I, et al. Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. *Journal of hepatology*. 1997;26(1):191-202. Epub 1997/01/01.
90. Lang CH, Frost RA, Svanberg E, Vary TC. IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats. *American journal of physiology Endocrinology and metabolism*. 2004;286(6):E916-26. Epub 2004/01/30.
91. Yurci A, Yucesoy M, Unluhizarci K, Torun E, Gursoy S, Baskol M, et al. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis. *Clinics and research in hepatology and gastroenterology*. 2011;35(12):845-54. Epub 2011/11/15.
92. Bergerson JT, Lee JG, Furlan A, Sourianarayanan A, Fetzer DT, Tevar AD, et al. Liver transplantation arrests and reverses muscle wasting. *Clinical transplantation*. 2015;29(3):216-21. Epub 2015/01/06.
93. Tsien C, Garber A, Narayanan A, Shah SN, Barnes D, Eghtesad B, et al. Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. *Journal of gastroenterology and hepatology*. 2014;29(6):1250-7. Epub 2014/01/22.

Table 1. Studies investigating the prognostic impact of sarcopenia in cirrhosis

Study type	n	Method for measuring muscle	%Sarcopenic / frail	Mortality risk*
Quantitative <i>(Durand et al, 2014)</i>	376	Transverse psoas muscle thickness / height (TPMT/height) by CT	nd	15% increase in mortality for each unit decrease in TPMT/height independent of MELD score

Quantitative (Kim et al, 2014)	89	TPMT by CT. Sarcopenia defined as <14mm/m	31%	HR 5.398 for mortality on multivariable analysis if sarcopenia present
Quantitative (Montano-Loza et al, 2012)	112	L3 skeletal muscle index by CT (SMI = muscle area / height <sup>2</sup> ), sarcopenia defined as <38.5cm/m <sup>2</sup> for women, <52.4cm/m <sup>2</sup> for men	40%	HR 2.26 for mortality on multivariable analysis if sarcopenia present
Quantitative (Tandon et al, 2012)	142	L3 SMI by CT, sarcopenia defined as <38.5cm/m <sup>2</sup> for women, <52.4cm/m <sup>2</sup> for men	41%	HR 2.36 for mortality on multivariable analysis if sarcopenia present
Quantitative (DiMartini et al, 2013)		L3-4 SMI by CT, sarcopenia defined as <38.5cm/m <sup>2</sup> for women, <52.4cm/m <sup>2</sup> for men	68%	HR 0.95 for POST-transplant mortality for each unit increase in SMI in men only (no significant impact in women)
Quantitative (Hanai et al, 2014)	130	L3 SMI by CT, sarcopenia defined as <38.5cm/m <sup>2</sup> for women, <52.4cm/m <sup>2</sup> for men	68%	HR 3.03 for mortality on multivariable analysis if sarcopenia present
Quantitative (Sinclair et al, 2015)	145	L4 SMI by CT, sarcopenia defined as <52.4cm/m <sup>2</sup> (men only)	70.3%	HR 1.05 for mortality on multivariable analysis for each unit decrease in SMI
Functional (Carey et al, 2010)	121	6 minute walk test, frail defined as <250 metres	nd	Each 100m reduction in 6min walk test associated with reduced survival (HR 0.48) independent of MELD score
Functional	294	Fried frailty index (FFI), frail defined	17%	45% increase in mortality with each


(Lai et al, 2014)		as $\geq 3$ out of a maximum of 5 points		1 point increase in FFI, independent of MELD
		Short physical performance battery (SPPB), frail defined as <9 of maximum 12 points	31%	19% increase in mortality with each 1 point decrease in SPPB, independent of MELD score
Functional (Alvares-de-silva et al, 2003)	50	Handgrip strength, frail defined as 2 standard deviations below the mean	63%	20.7% 12 month mortality in frail patients vs 0% in non-frail patients

\*All mortality results displayed were considered significant with a p value <0.05

Table 2. Therapeutic Interventions for sarcopenia in cirrhosis

Intervention	Administration	Mechanism	Evidence
High energy, high protein diet	1 - 1.5 grams of protein per kg of body weight per day (total 35–40kcal/kg total energy intake per day)	Improves nitrogen balance	4.3 +/- 3.2 g of nitrogen/day on a high energy, high protein diet versus -2.2 +/- 1.9 g/day on usual diet, p=0.01 (Dichi et al)
Late evening snack	Complex carbohydrate snack with protein such as cheese on wholemeal bread	Minimises muscle breakdown during overnight fasting in the context of low hepatic glycogen stores	Metanalysis revealed increased respiratory quotient (increased use of glucose) and nitrogen balance and reduced muscle protein breakdown (Tsien et al)
BCAA supplementation	Oral granules leucine/isoleucine/valine 7.5g/3.75g/3.75g (dissolved in carbonated beverage)	Activate muscle protein synthesis via mTOR signalling pathway	BCAA reduced whole body protein Ra (representing reduced proteolysis) and increased GCN2 (muscle regulator of mTOR activity), p<0.01 (Tsien et al)
Exercise	We recommend 30 minutes of moderate intensity walking 3-4 times per week in combination with resistance training such as light hand weights 3 times per week as tolerated	Activates IGF-1 which results in increased mTOR signalling and down-regulation of muscle breakdown via the UPP	Nil. But strongly recommended

Testosterone therapy	Intramuscular testosterone decanoate or topical testosterone gel as per manufacturers recommendations	Activates androgen receptors in muscle which inhibits myostatin, activates muscle protein synthesis via the mTOR pathway and down-regulates the UPP	Testosterone gel in 12 hypogonadal men with cirrhosis increased handgrip strength from 34.03 +/- 7.24kg to 39.18 +/- 5.99kg, p<0.001, nb no control group ( <i>Yurci et al</i> )
Normalisation of portal HTN	Insertion of trans-jugular intra-hepatic porto-systemic shunt	Unknown. May improve nutrient absorption by reducing gastropathy/enteropathy, and may reduce systemic inflammatory driver of muscle breakdown	Psoas muscle area improved in 41 of 57 patients with a mean increase from 22.8 +/- 0.9 to 25.1 +/- 0.9 cm <sup>2</sup> , p<0.001. ( <i>Tsien et al</i> )
Rifaximin	550mg twice daily	Hypothetically may down-regulate myostatin levels by reducing serum ammonia which may also release more BCAAs for use as muscle fuel	Nil. Theoretical only
IGF-1 therapy Myostatin blockers	Research use only	Increases mTOR signalling Reduces myostatin-induced blockage of satellite cell differentiation and proliferation	No human studies



apt\_13549\_f1.eps

# Author Manuscript



Minerva Access is the Institutional Repository of The University of Melbourne

**Author/s:**

Sinclair, M; Gow, PJ; Grossmann, M; Angus, PW

**Title:**

Review article: sarcopenia in cirrhosis - aetiology, implications and potential therapeutic interventions

**Date:**

2016-04-01

**Citation:**

Sinclair, M., Gow, P. J., Grossmann, M. & Angus, P. W. (2016). Review article: sarcopenia in cirrhosis - aetiology, implications and potential therapeutic interventions. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 43 (7), pp.765-777.

<https://doi.org/10.1111/apt.13549>.

**Persistent Link:**

<http://hdl.handle.net/11343/290914>

**File Description:**

Accepted version